Migraines impact an estimated 14 to 15 percent of the global population, and yet the few medications we have on hand do not work for everybody
and total flavonoids) and the antioxidant activity of all extracts (Zhuang et al., 2022)
Valsartan Valsartan inhibits the pressor effect of angiotensin II infusions
With TrumpRx and cash-pay commoditization threatening Ro's D2C margins , the emerging battlefield shifts to the employer benefits market where 160 million Americans with employer-sponsored insurance face 85% plan restriction rates on GLP-1 coverage for weight loss, putting Ro on a collision course with Omada Health ($450M raised, U.S
October 3, 2025- As of October 3, 2025, there are over 2,809 lawsuits in the MDL pertaining to Ozempic, Mounjaro and numerous other GLP-1 medications